CAPTRUST Financial Advisors
SPRB

CAPTRUST Financial Advisors’s Spruce Biosciences SPRB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20
Closed -$7K – 5175
2021
Q4 		$7K Buy
+20
New +$5.95K ﹤0.01% 3939

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

CAPTRUST Financial Advisors's SPRB Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Spruce Biosciences (SPRB) in Q1 2022, closing a stake of 20 shares — an estimated $7K sold.

CAPTRUST Financial Advisors first reported a position in SPRB in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 43 funds tracked by Wall St. Rank hold SPRB as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Spruce Biosciences position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 20 Spruce Biosciences shares in Q1 2022, an estimated $7K.
  • CAPTRUST Financial Advisors first reported a position in Spruce Biosciences in Q4 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Spruce Biosciences position peaked at $7K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.